Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | MKC-3946 |
| Trade Name | |
| Synonyms | MKC 3946|MKC3946 |
| Drug Descriptions |
MKC-3946 is small molecule drug that targets the endoribonuclease domain of Ire1 alpha (ERN1) and inhibits XBP1 splicing, potentially resulting in increased apoptosis and decreased tumor growth (PMID: 22538852). |
| DrugClasses | |
| CAS Registry Number | 1093119-54-0 |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BMI-135 + MKC-3946 | BMI-135 MKC-3946 | 0 | 0 |
| Bortezomib + MKC-3946 | Bortezomib MKC-3946 | 0 | 0 |
| MKC-3946 | MKC-3946 | 0 | 0 |
| MKC-3946 + Tanespimycin | MKC-3946 Tanespimycin | 0 | 0 |